Sunday, December 15, 2024

Tag: Pfizer MATISSE Trial Targets Pregnant Women for Bivalent RSV Vaccine

Pfizer MATISSE Trial Targets Pregnant Women for Bivalent RSV Vaccine

    0

    by Dr. Peter McCullough, Global Research:

    Vaccine ideology or hubris appears everywhere! Never had we heard so much about vaccines in our day to day life as laypersons or as healthcare professionals. This certainly is the case for respiratory syncytial virus (RSV) which is largely an infantile problem easily treated with nebulizers when it occurs. Now Pfizer is aggressively testing their investigational bivalent RSV prefusion protein vaccine which contains stabilized preF glycoproteins from the two main cocirculating antigenic subgroups (RSV A and RSV B). Is this really needed? Should pregnant women be put at risk even before product launch for the general childhood population? We can see now that emboldened Pfizer is breaking new ground with clinical trials in late term pregnancy.